Literature DB >> 2026440

Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route.

A M Mowat1, A M Donachie, G Reid, O Jarrett.   

Abstract

Induction of all forms of protective immunity by oral immunization with subunit vaccines is an ideal goal for the development of novel vaccines, but creates several theoretical problems from the point of view of antigen processing mechanisms. We show here that incorporation of the protein antigen ovalbumin (OVA) in lipophilic immune-stimulating complexes (ISCOMS) induces very strong primary immune responses in mice and requires very small amounts of antigen. OVA ISCOMS were particularly efficient at stimulating T-cell-mediated immunity in vivo, including delayed-type hypersensitivity (DTH) and potent class I major histocompatibility complex (MHC)-restricted cytotoxic T-cell responses. Furthermore, unlike native protein, OVA in ISCOMS was immunogenic when given orally. Thus, ISCOMS seem to allow protein to enter both the endogenous and exogenous pathways of antigen processing and overcome the usual induction of tolerance after feeding antigen. ISCOMS could provide potentially useful adjuvants for the development of oral subunit vaccines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2026440      PMCID: PMC1384389     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

Review 1.  Pathways of viral antigen processing and presentation to CTL: defined by the mode of virus entry?

Authors:  E O Long; S Jacobson
Journal:  Immunol Today       Date:  1989-02

2.  Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo.

Authors:  G Y Ishioka; S Colon; C Miles; H M Grey; R W Chesnut
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

3.  The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes.

Authors:  K Lövgren
Journal:  Scand J Immunol       Date:  1988-02       Impact factor: 3.487

4.  Class I-restricted presentation occurs without internalization or processing of exogenous antigenic peptides.

Authors:  N A Hosken; M J Bevan; F R Carbone
Journal:  J Immunol       Date:  1989-02-15       Impact factor: 5.422

5.  Serological responses in cats vaccinated with FeLV ISCOM and an inactivated FeLV vaccine.

Authors:  A Osterhaus; K Weijer; F UytdeHaag; P Knell; O Jarrett; L Akerblom; B Morein
Journal:  Vaccine       Date:  1989-04       Impact factor: 3.641

6.  Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulatory complexes (iscoms).

Authors:  P D Jones; R Tha Hla; B Morein; K Lovgren; G L Ada
Journal:  Scand J Immunol       Date:  1988-06       Impact factor: 3.487

7.  Control of infectious bovine rhinotracheitis in calves with a BHV-1 subunit-ISCOM vaccine.

Authors:  M Trudel; G Boulay; C Séguin; F Nadon; G Lussier
Journal:  Vaccine       Date:  1988-12       Impact factor: 3.641

8.  Cells process exogenous proteins for recognition by cytotoxic T lymphocytes.

Authors:  J W Yewdell; J R Bennink; Y Hosaka
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

9.  Measles virus fusion protein presented in an immune-stimulating complex (iscom) induces haemolysis-inhibiting and fusion-inhibiting antibodies, virus-specific T cells and protection in mice.

Authors:  P de Vries; R S van Binnendijk; P van der Marel; A L van Wezel; H O Voorma; B Sundquist; F G Uytdehaag; A D Osterhaus
Journal:  J Gen Virol       Date:  1988-03       Impact factor: 3.891

10.  Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides.

Authors:  F R Carbone; M W Moore; J M Sheil; M J Bevan
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

View more
  27 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

Review 2.  Oral delivery of vaccines. Formulation and clinical pharmacokinetic considerations.

Authors:  D T O'Hagan
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

3.  The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes.

Authors:  Neil C Robson; Helen Beacock-Sharp; Anne M Donachie; Allan McI Mowat
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

4.  Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles.

Authors:  K J Maloy; A M Donachie; D T O'Hagan; A M Mowat
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

5.  Human HLA class I- and HLA class II-restricted cloned cytotoxic T lymphocytes identify a cluster of epitopes on the measles virus fusion protein.

Authors:  R S van Binnendijk; J P Versteeg-van Oosten; M C Poelen; H F Brugghe; P Hoogerhout; A D Osterhaus; F G Uytdehaag
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

6.  Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain.

Authors:  J N Flynn; C A Cannon; G Reid; M A Rigby; J C Neil; O Jarrett
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

7.  Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice.

Authors:  H O Ghazi; M Erturk; L M Stannard; M Faulkner; C W Potter; R Jennings
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

8.  Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis.

Authors:  R Schirmbeck; K Melber; T Mertens; J Reimann
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

9.  Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens.

Authors:  J C Bowen; S K Nair; R Reddy; B T Rouse
Journal:  Immunology       Date:  1994-03       Impact factor: 7.397

10.  Antigen presentation by naive macrophages, dendritic cells and B cells to primed T lymphocytes and their cytokine production following exposure to immunostimulating complexes.

Authors:  M Villacres-Eriksson
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.